Raleigh-based Valencell and Durham-based Validic, two startups that are emerging as global leaders in mobile health technology, demonstrated their respective advances at an FDA expo on Monday at the invitation of the FDA and co-sponsor Consumer Technology Association.
Judges affiliated with the CTA had chosen Valencell as “Small Business of the Year” among its 2016 Entrepreneur Innovation award winners announced last week.
“Valencell’s technology is focused on creating the most accurate wearables for applications including sports and fitness, health, gaming and first responders. The company’s success derives from a passion to enable people to live healthier, fuller lives through biometric wearable technologies,” the CTA said.
“Accuracy in all conditions is at the heart of what Valencell does – anyone, anywhere, doing anything, wearing any device. Valencell’s biometrics lab puts consumer products through rigorous testing on people with a wide range of skin tones, physical ability and ages to validate real world accuracy.”
Valencell has developed multiple patent-winning technology (PerformTek) for sensors in a variety of wearable mobile health devices.
Validic, meanwhile, has developed technology for integrating health data across multiple platforms.
Executives from the two companies also are participating in WRAL TechWire’s Executive Exchange event on Tuesday in Raleigh.The event is titled “The Future of Mobile Health.” It includes a keynote address from Joanne Rohde, CEO of Axial Exchange as well as two panel discussions.
A few tickets remain available.
FDA event
The FDA Digital Health Technology Expo took place at FDA’s headquarters in Silver Spring, Md.
Also participating were Philips, Qualcomm, Sony, Samsung, Fossil/Misfit, and others.
“Valencell will be demonstrating its groundbreaking biometric sensor technology and its ability to accurately measure RR-interval [related to heart rate] in wearable devices worn in numerous form-factors. Accurate RR-interval data is critical to the wearable health monitoring marketplace because this data is required for assessments of heart rate variability (HRV), atrial fibrillation, arrhythmia, stress analysis, and various cardiovascular conditions,” Valencell noted.
WRAL TechWire reported recently about Valencell’s deal to include its technology in a Chinese firm’s smartwatch.
“We are honored to be invited by the CTA and FDA to participate in this event, and to have the opportunity to showcase some of our latest innovations in biometric data sensor technology for health applications, including accurate continuous RR-interval monitoring technology that can ultimately be used for important health screening applications and fitness assessments,” said Dr. Steven LeBoeuf, the president and co-founder of Valencell. “The goal of Valencell’s innovation in wearable technology is to make biometric monitoring easy, affordable, and seamless with everyday living, so that more accurate data can be taken frequently enough to drive personalized health insights and guidance. We look forward to working with government and industry groups, and our partners, to help drive continued growth in this market.”
Validic, meanwhile, recently published a research paper about the increasing importance of digital health data.
“According to survey results, over 60 percent of respondents stated they have used digital health technologies in clinical trials and over 97 percent said they plan to use these tools increasingly over the next five years. Findings from the survey point to the increasing prevalence of technology-driven clinical trials and growing need for automated access to real-time, remotely-collected patient data,” Validic reported.
